AC Immune (ACIU) Net Cash Flow (2015 - 2025)

AC Immune (ACIU) has reported Net Cash Flow for 11 consecutive years, with -$909600.4 the latest figure, recorded in Q4 2025.

• In Q4 2025, Net Cash Flow fell 141.7% year-over-year to -$909600.4; the TTM figure through Mar 2026 stood at $10.8 million (up 128.43% YoY), while the FY2025 annual figure was -$10.2 million, up 78.0% from the prior year.
• Net Cash Flow slipped to -$909600.4 in Q4 2025 per ACIU's latest filing, from $2.4 million in the prior quarter.
• Across five years, Net Cash Flow topped out at $54.0 million in Q4 2023 and bottomed at -$51.2 million in Q2 2021.
• Historically, Net Cash Flow has averaged -$7.1 million across 5 years, with a median of -$11.6 million in 2021.
• Annual changes were most pronounced in 2021 — Net Cash Flow slumped 1408.62% — and 2023, when it surged 513.24%.
• AC Immune's Net Cash Flow stood at -$11.7 million in 2021, then slipped by 11.48% to -$13.1 million in 2022, then soared by 513.24% to $54.0 million in 2023, then tumbled by 95.96% to $2.2 million in 2024, then plunged by 141.7% to -$909600.4 in 2025.
• Business Quant data shows ACIU's Net Cash Flow at -$909600.4 in Q4 2025, $2.4 million in Q3 2025, and $9.3 million in Q2 2025.